BEIGF (BeOne Medicines) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEIGF BeOne Medicines Ltd BEIGF
61 GF Score
Price $21.95
GF Value $26.62
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BEIGF
61GF Score
BeOne Medicines Ltd BEIGF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BeOne Medicines (BEIGF) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $21.95 is trading 17.6% below its estimated GF Value™ of $26.62. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for BEIGF:

  • Dividends Received:
  • GF Value™: $26.62 vs. price of $21.95 (17.6% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
61GF Score

Get the complete analysis for BEIGF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.95
Price
$26.62
GF Value